A practical reference on visceral adipose tissue: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 44-residue peptide | GHRH analog backbone |
| Approximate molecular mass | 5136 Da | Varies with counterion and hydration state |
| N-terminal group | trans-3-hexenoyl | Increases resistance to dipeptidyl peptidase IV |
| Primary receptor | GHRH receptor (GHRHR) | Class B G protein-coupled receptor on somatotrophs |
| Principal mediator | IGF-1 | Rises indirectly after growth hormone release |
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
研究背景集中在特定人群的体成分改变，尤其是与脂肪分布异常相关的内脏脂肪堆积。不同地区对它的监管状态与获批适应症并不一致，部分市场仅限特定诊断人群使用。在一般人群中的长期效应、与其他激素的相互作用以及停药后的维持情况仍属开放问题，现有数据不足以给出普遍结论。
tesamorelin 是一种人工合成的四十四肽，序列与内源性生长激素释放激素（GHRH）的 1-44 片段一致，区别在于 N 端加接了一个反式-3-己烯酰基。该修饰抑制二肽基肽酶 IV 的快速切割，从而延长分子在循环中的存留时间。作为肽类分子，它难以经胃肠道吸收，文献中讨论的均是注射途径。分类上通常把它归为 GHRH 类似物，以区别于生长激素本身。
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
=== Pharmacodynamics === Although the mechanism of action of valproate is not fully understood, traditionally, its anticonvulsant effect has been attributed to the blockade of voltage-gated sodium channels and increased brain levels of the inhibitory synaptic neurotransmitter gamma-aminobutyric acid (GABA). The GABAergic effect is also believed to contribute towards the anti-manic properties of valproate. In animals, sodium valproate raises cerebral and cerebellar levels of GABA, possibly by inhibiting GABA degradative enzymes, such as GABA transaminase, succinate-semialdehyde dehydrogenase and by inhibiting the re-uptake of GABA by neuronal cells. Prevention of neurotransmitter-induced hyperexcitability of nerve cells via Kv7.2 channel and AKAP5 may also contribute to its mechanism. Valproate has been shown to protect against a seizure-induced reduction in phosphatidylinositol (3,4,5)-trisphosphate (PIP3) as a potential therapeutic mechanism.
=== Francophone Affairs === Mulroney voted in support of the Ford government's September 2018 proposal to use Section 33 of the Canadian Charter of Rights and Freedoms, commonly called the "notwithstanding clause", to overrule a judge's decision that legislation intended to shrink the size of Toronto City Council was in fact in violation of Charter rights. For this position, she faced widespread condemnation from constitutional experts and politicians of all parties, particularly with respect to her duty to ensure the sanctity of the judicial process as Attorney General. In November 2018, Ford announced cuts which included cancelling a "French language university and cut the post of provincial commissioner for French language affairs." Ontario's francophone population represents from 550,000 to 744,000 people in a province of 14 million, according to The New York Times with many concentrated in Sudbury, Ontario, in northern Ontario and near the Ontario-Quebec border in eastern Ontario. The Ford government again came under criticism from the Franco-Ontarian community for its perceived inaction during the 2021 Laurentian University Financial Crisis and its support of the large cuts to the university.
Madera Community Hospital is a not-for-profit community health resource and is not associated with any other hospital or health system. The hospital is locally governed by a board of trustees which provides governance and oversight. The board is composed of over a dozen community and business leaders. Madera Community Hospital was founded in 1971 and is located at 1250 E. Almond Avenue in Madera, California. The hospital contained 106 acute care beds, a 16-bed Emergency Department, and a 10-bed Intensive Care Unit. Madera Community Hospital also operates two rural health care clinics (Mendota and Chowchilla) and a home health agency (Family Health Services in Madera). Madera Community Hospital is fully accredited by the American Osteopathic Association's Healthcare Facilities Accreditation Program (HFAP), by the Clinical Laboratory Improvement Act, 1988 (CLIA) program, and is a member of the Hospital Council of Northern and Central California and the California Healthcare Association. The COVID-19 pandemic overwhelmed San Joaquin Valley hospitals. Already financially stressed, increasing costs for medical equipment and salaries for traveling nurses to address the surges were too much for the hospital to absorb. On January 3, 2023, Madera Community Hospital shuttered and filed for bankruptcy. American Advanced Management is currently working to reopen the facility.
== Selected publications == Balalaie, S.; Hashtroudi, M. S.; Arabanian, A. (2000). "One-pot synthesis of tetrasubstituted imidazoles catalyzed by zeolite HY and silica gel under microwave irradiation". Green Chemistry. 2 (6): 274–276. doi:10.1039/b006201o. Balalaie, S.; Bararjanian, M.; Amani, A. M.; Movassagh, B. (2006). "(S)-Proline as a neutral and efficient catalyst for the one-pot synthesis of tetrahydrobenzo [b] pyran derivatives in aqueous media". Synlett. 2006 (2): 263–266. doi:10.1055/s-2005-923606. Bararjanian, M.; Balalaie, S.; Rominger, F.; Movassagh, B.; Bijanzadeh, H. R. (2010). "Six-component reactions for the stereoselective synthesis of 3-arylidene-2-oxindoles via sequential one-pot Ugi/Heck carbocyclization/Sonogashira/nucleophilic addition". The Journal of Organic Chemistry. 75 (9): 2806–2812. doi:10.1021/jo902713x. PMID 20387848. Balalaie, S.; Bararjanian, M.; Hosseini, M.S.; Bigdeli, Z. (2006). "One-pot synthesis of 1,4-dihydropyridine derivatives in a solvent-free condition". Helvetica Chimica Acta. 89 (8): 1769–1773. doi:10.1002/hlca.200690161. Balalaie, S.; Sharafi-Kolkesh, A. (2003). "A novel and efficient one-pot synthesis of 2,4,6-triarylpyridines under solvent-free conditions". Zeitschrift für Naturforschung B. 58 (10): 1075–1077. doi:10.1515/znb-2003-1021.
Alcohol consumption is fully legal and available in most countries of the world. Home made alcoholic beverages with low alcohol content like wine, and beer is also legal in most countries, but distilling moonshine outside of a registered distillery remains illegal in most of them. Some majority-Muslim countries, such as Saudi Arabia, Kuwait, Pakistan, Iran, and Libya prohibit the production, sale, and consumption of alcoholic beverages because they are forbidden by Islam. Also, laws banning alcohol consumption are found in some Indian states as well as some Native American reservations in the U.S. In addition, there are regulations on alcohol sales and use in many countries throughout the world. For instance, the majority of countries have a minimum legal drinking age to purchase or consume alcoholic beverages, although there are often exceptions such as underage consumption of small amounts of alcohol with parental supervision. Also, some countries have bans on public intoxication. Drinking while driving or intoxicated driving is frequently outlawed, and it may be illegal to have an open container of alcohol or liquor bottle in an automobile, bus, or aircraft. The legality of sex under alcohol influence varies by country and the threshold of "too drunk" for sexual consent can be ambiguous.
Sources: en.wikipedia.org
Peukert argued that the very growth of the welfare state under the Weimar Republic ensured the backlash when social problems were not solved was especially severe. Peukert wrote: "Weimar installed the new principle of the social state, in which, on the one hand, the citizen could now claim public assistance in (his/her) social and personal life, while on the other, the state set up the institutional and normative framework, (defining how) a 'normal' life of the citizen of the state could progress...This process, which had already began before the turn of the century, reached its apex in the Weimar Republic and was also thrown into crisis, as the limits of social technology could achieve were reached in every direction". Peukert wrote that after the First World War, the pre-war mood of optimism gave way to disillusionment as German bureaucrats found social problems to be more insolvable than at first thought, which in turn, guided by the prevailing Social Darwinist and eugenicist values led them to place increasing emphasis on saving the biologically "fit" while the biologically "unfit" were to be written off. Peukert used as an example the fact that social workers had before the First World War had believed it was possible to ensure that every child in Germany was brought up in a happy home and by 1922 were instead declaring that certain young people were "biologically" prone to being "unfit", requiring a law on detention that was to remove them from society forever.
A combination of cilofexor/firsocostat was studied in people with bridging fibrosis and cirrhosis. It was observed to have led to improvements in NASH activity with a potential antifibrotic effect. Lanifibranor is also shown to prevent worsening fibrosis.
=== For Alzheimer's disease === Several companies are in the early stages of development and testing of this potential class of treatment. In March 2008 phase I results were reported for CoMentis Inc's candidate CTS-21166. In April 2012 Merck & Co., Inc reported phase I results for its candidate verubecestat (MK-8931). Merck began a Phase II/III trial of MK-8931 in December, 2012 estimated to be completed in July 2019. In February 2017, Merck halted its late-stage trial of verubecestat for mild to moderate Alzheimer's disease after it was reported as having "virtually no chance" of working according to an independent panel of experts. This came just three months after Eli Lilly & Co. announced its own setback with solanezumab. In September 2014 AstraZeneca and Eli Lilly and Company announced an agreement to codevelop lanabecestat (AZD3293). A pivotal Phase II/III clinical trial of lanabecestat started in late 2014, but was halted in 2018 before its planned conclusion due to poor results. Another BACE1 inhibitor that has reached phase II trials is the Eli Lilly's inhibitor LY2886721. The data on phase I trial were first presented at the Alzheimer's Association International conference in 2012. Daily dosing during 2 weeks, reduced BACE1 activity by 50–75% and CSF Aβ42 by 72% (Willis et al., 2012; Bowman Rogers and Strobel, 2013). Recently, Lilly reported that the phase II trial of LY2886721 was terminated due to liver abnormalities that were found in 4 out of 45 patients (Rogers, 2013).
== Battle honours == In the British Army, battle honours are awarded to regiments that have seen active service in a significant engagement or campaign, generally with a victorious outcome. The Special Air Service Regiment has been awarded the following battle honours:
Sources: en.wikipedia.org
The French word absinthe can refer either to the alcoholic beverage, or less commonly, to the actual wormwood plant. Absinthe is derived from the Latin absinthium, which in turn comes from the Greek ἀψίνθιον apsínthion 'wormwood'. Some argue that the word means "undrinkable" in Greek, but it may instead be linked to the Persian root, in Persian called spand or aspand or the variant esfand, which meant Peganum harmala, also called Syrian rue in English, although it is not a variety of rue, another famously bitter herb. That Artemisia absinthium was commonly burned as a protective offering may suggest that its origins lie in the reconstructed Proto-Indo-European language root *spend, meaning "to perform a ritual" or "make an offering". Whether the word was a borrowing from Persian into Greek, or from a common ancestor of both, is unclear. Alternatively, the Greek word may originate in a pre-Greek substrate word, marked by the non-Indo-European consonant complex -νθ -nth. Alternative spellings for absinthe include absinth, absynthe, and absenta. Absinth (without the final e) is a spelling variant most commonly applied to absinthes produced in central and eastern Europe, and is specifically associated with Bohemian-style absinthes.
== History == Before amylin deposition was associated with diabetes, already in 1901, scientists described the phenomenon of "islet hyalinization", which could be found in some cases of diabetes. A thorough study of this phenomenon was possible much later. In 1986, the isolation of an aggregate from an insulin-producing tumor was successful, a protein called IAP (Insulinoma Amyloid Peptide) was characterized, and amyloids were isolated from the pancreas of a diabetic patient, but the isolated material was not sufficient for full characterization. This was achieved only a year later by two research teams whose research was a continuation of the work from 1986.
== Overdose == LSD at typical recreational doses (~50–250 μg) is considered to be very safe in terms of toxicity, with not a single toxicity-related death having been reported at such doses despite many millions of exposures. In addition, LSD is considered to be a relatively non-toxic drug in overdose. The highest dose of LSD evaluated in clinical trials in humans has been 800 μg (0.8 mg), or 8 times the typical recreational dose of 100 μg. However, other studies reported use of doses of up to 2,000 μg intramuscularly in some individuals, or more than 20 times the typical dose. It is estimated, based on animal studies and human case reports, that the lethal dose of LSD in humans is approximately 100 mg, or 1,000 times the typical dose. There have been a handful of reported cases of fatal overdose with LSD as of 2024. However, critical review of the literature by David E. Nichols found that of five identified cases, one was not consistent with the effects of LSD but instead may have been another drug like 25I-NBOMe; two involved normal doses of LSD in individuals who were placed in maximal physical restraint (hogtied) by police followed by presumed positional asphyxia and fatal cardiovascular collapse (hogtying being a practice that is associated with accidental death generally); and two were associated with massive LSD overdose involving doses of possibly more than 300 mg. Besides death due to toxicity, LSD is rarely associated with death via suicide, accidents, or violent encounters due to induction of abnormal behavior.
Tafamidis was shown to have a greater effect when started earlier in the disease course, when milder disease was present, as amyloid deposits in the heart were lower. Acoramidis also showed a reduction in mortality in those with TTR amyloidosis compared to placebo and a reduction in hospitalizations related to heart disease. Tafamidis is considered a first line option for the treatment of TTR amyloidosis. Ten to 20% of those with ATTR amyloidosis required pacemakers, usually due to high degree atrioventricular blocks. Observational cohort data showed that biventricular pacing preserves left ventricular function, heart failure symptom scores and mitral regurgitation incidence compared to right ventricular pacing. Ventricular arrythmia are common in those with AL and ATTR amyloidosis and are associated with a higher risk of sudden cardiac death. However, the use of implantable cardioverter defibrillators remains questionable in cardiac amyloidosis (both light chain and ATTR amyloidosis) and a mortality benefit has not been consistently shown. Outside of standard indications for implantable cardioverter defibrillators for those with heart failure, specific benefits in those with cardiac amyloidosis are not well established. Two to 5% of people with ATTR amyloidosis experience sudden cardiac death.
== Mechanism of action == Phenazopyridine's mechanism of action is not well known, and only basic information on its interaction with the body is available. It is known that the chemical has a direct topical analgesic effect on the mucosa lining of the urinary tract. It is rapidly excreted by the kidneys directly into the urine. Hydroxylation is the major form of metabolism in humans, and the azo bond is usually not cleaved. On the order of 65% of an oral dose will be secreted directly into the urine chemically unchanged.
Sources: en.wikipedia.org
The amino acid sequence matches human growth hormone-releasing hormone, but the amino terminus carries a trans-3-hexenoyl group instead of a free amine. That single structural change chiefly affects enzymatic stability rather than receptor selectivity.
Growth hormone released from the pituitary stimulates IGF-1 production in the liver and other tissues, so circulating IGF-1 generally rises during exposure. The size of the rise varies between individuals and depends on baseline hormonal status and other concurrent factors.
Reported imaging studies focus on visceral adipose tissue, where reductions are more consistently observed across trials. Subcutaneous depots show smaller and less reproducible changes, so the two compartments should not be treated as equivalent.
It mirrors the 44-residue form of human growth hormone-releasing hormone. A hexenoyl group on the N-terminal tyrosine distinguishes it from the unmodified hormone. The change is intended to improve resistance to enzymatic breakdown.